Cabozantinib (Cabometyx/Cometriq)[ ANTI-CANCER DRUGS ]
sold under the brand-name Cabometyx and Cometriq
Product DetailsMedication used to treat medullary thyroid cancer and a second line treatment for renal cell carcinoma among others. It is a small molecule inhibitor of the tyrosine kinases c-Met and VEGFR2, and also inhibits AXL and RET. It was discovered and developed by Exelixis Inc.